Sofosbuvir/velpatasvir or glecaprevir/pibrentasvir for treating patients with hepatitis C virus reinfection following direct‐acting antiviral‐induced sustained virologic response
Open Access
- 14 October 2021
- journal article
- research article
- Published by Wiley in Advances in Digestive Medicine
- Vol. 10 (1), 34-42
- https://doi.org/10.1002/aid2.13302
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysisClinical Infectious Diseases, 2016
- Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 InfectionThe New England Journal of Medicine, 2015
- Comparison of Abbott RealTime HCV Genotype II with Versant Line Probe Assay 2.0 for Hepatitis C Virus GenotypingJournal of Clinical Microbiology, 2015
- High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current MethodsJournal of Clinical Microbiology, 2015
- Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infectionGut, 2014
- Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virusJournal of Hepatology, 2014
- Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfaInternational Journal of Nanomedicine, 2014
- A Sustained Virologic Response Is Durable in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and RibavirinGastroenterology, 2010
- Non-invasive evaluation of liver fibrosis using transient elastographyJournal of Hepatology, 2008
- Hepatitis C Virus InfectionThe New England Journal of Medicine, 2001